Short review on dopamine agonists: Insight into clinical and research studies relevant of Parkinson's disease

Pharmacological Reports

Volumn 57, Issue 6, 2005, Pages 701-712

  Radad, Khaled ^a   Gille, Gabrielle ^b   Rausch, Wolf Dieter ^a  

^a UNIVERSITY OF VETERINARY MEDICINE   (Austria)

^b DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

Author keywords

Dopamine agonists; Dopaminergic neurons; Levodopa; Parkinson's disease

Indexed keywords

APOMORPHINE; BROMOCRIPTINE; CABERGOLINE; DIHYDROERGOCRYPTINE; DOPAMINE; DOPAMINE 1 RECEPTOR; DOPAMINE 2 RECEPTOR; DOPAMINE 3 RECEPTOR; DOPAMINE 4 RECEPTOR; DOPAMINE 5 RECEPTOR; DOPAMINE RECEPTOR STIMULATING AGENT; LEVODOPA; LISURIDE; PERGOLIDE; PRAMIPEXOLE; ROPINIROLE; ROTIGOTINE;

ADJUVANT THERAPY; ANTIOXIDANT ACTIVITY; CLINICAL TRIAL; DOPAMINE METABOLISM; DOPAMINERGIC TRANSMISSION; DOSE RESPONSE; DRUG ABSORPTION; DRUG ANTAGONISM; DRUG BLOOD LEVEL; DRUG CHOICE; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG OXIDATION; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG TOLERABILITY; DYSKINESIA; HUMAN; LONG TERM CARE; MENTAL DISEASE; MOOD DISORDER; MOTOR DYSFUNCTION; NEUROTOXICITY; NONHUMAN; PARKINSON DISEASE; PROTEIN LOCALIZATION; PSYCHOSIS; REVIEW; VALVULAR HEART DISEASE;

EID: 33645675839     PISSN: 22995684     EISSN: 22995684     Source Type: Journal    
DOI: None     Document Type: Review

References (144)

1. Abramova NA, Cassarino DS, Khan SM, Painter TW, Bennett JP Jr.: Inhibition by R(+) or S(-) pramipexole of caspase activation and cell death induced by methylpyridinium ion or beta amyloid peptide in SH-SY5Y neuroblastoma. J Neurosci Res, 2002, 67, 494-500.
2. Adams JD Jr., Odunze IN: Oxygen free radicals and Parkinson's disease. Free Radic Biol Med, 1991, 10, 161-169.
3. Albin RL, Young AB, Penney JB: The functional anatomy of basal ganglia disorders. Trends Neurosci, 1989, 12, 366-375.
4. Alexander T, Sortwell CE, Sladek CD, Roth RH, Steece-Collier K: Comparison of neurotoxicity following repeated administration of L-dopa, D-dopa and dopamine to embryonic mesencephalic dopamine neurons in cultures derived from Fisher 344 and Sprague-Dawley donors. Cell Transplant, 1997, 6, 309-315.
5. Allen R, Becker PM, Bogan R, Schmidt M, Kushida CA, Fry JM, Poceta JS, Winslow D: Ropinirole decreases periodic leg movements and improves sleep parameters in patients with restless legs syndrome. Sleep, 2004, 27, 907-914.
6. Anderson DW, Neavin T, Smith JA, Schneider JS: Neuroprotective effects of pramipexole in young and aged MPTP-treated mice. Brain Res, 2001, 905, 44-53.
7. Antkiewicz-Michaluk L: Endogenous risk factors in Parkinson's disease: dopamine and tetrahydroisoquinolines. Pol J Pharmacol, 2002, 54, 567-572.
8. Arai N, Isaji M, Kojima M, Mizuta E, Kuno S: Combined effects of cabergoline and L-dopa on parkinsonism in MPTP-treated cynomolgus monkeys. J Neural Transm, 1996, 103, 1307-1316.
9. Asanuma M, Ogawa N, Nishibayashi S, Kawai M, Kondo Y, Iwata E: Protective effects of pergolide on dopamine levels in the 6-hydroxydopamine-lesioned mouse brain. Arch Int Pharmacodyn Ther, 1995, 329, 221-230.
10. Baseman DG, O'Suilleabhain PE, Reimold SC, Laskar SR, Baseman JG, Dewey RB Jr: Pergolide use in Parkinson's disease is associated with cardiac valve regurgitation. Neurology, 2004, 63, 301-304.
11. Battaglia G, Busceti CL, Cuomo L, Giorgi FS, Orzi F, De Blasi A, Nicoletti F et al.: Continuous subcutaneous infusion of apomorphine rescues nigro-striatal dopaminergic terminals following MPTP injection in mice. Neuropharmacology, 2002, 42, 367-373.
12. Battistin L, Bardin PG, Ferro-Milone F, Ravenna C, Toso V, Reboldi G: Alpha-dihydroergocryptine in Parkinson's disease: a multicentre randomized double blind parallel group study. Acta Neurol Scand, 1999, 99, 36-42.
13. Bergamasco B, Frattola L, Muratorio A, Piccoli F, Mailland F, Parnetti L: Alpha-dihydroergocryptine in the treatment of de novo parkinsonian patients: results of a multicentre, randomized, double-blind, placebo-controlled study. Acta Neurol Scand, 2000, 101, 372-380.
14. Bernocchi G, Gerzeli G, Scherini E, Vignola C: Neuroprotective effects of alpha-dihydroergocryptine against damages in the substantia nigra caused by severe treatment with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Acta Neuropathol (Berl), 1993, 85, 404-413.
15. Birkmayer W, Hornykiewicz O: The effect of 1-3,4-dihydroxyphenylalanine (= DOPA) on akinesia in parkinsonism. 1961. Wien Klin Wochenschr, 2001, 113, 851-854.
16. Blin O: The pharmacokinetics of pergolide in Parkinson's disease. Curr Opin Neurol, 2003, 16, Suppl 1, S9-S12.
17. Bonuccelli U: Comparing dopamine agonists in Parkinson's disease. Curr Opin Neurol, 2003, 16, Suppl 1, S13-S19.
18. Bonuccelli U, D'Antonio P, D'Avino C, Piccini P, Muratorio A: Dihydroergocryptine in the treatment of Parkinson's disease. J Neural Transm Suppl, 1995, 45, 239-245.
19. Bouthenet ML, Souil E, Martres MP, Sokoloff P, Giros B, Schwartz JC: Localization of dopamine D3 receptor mRNA in the rat brain using in situ hybridization histochemistry: comparison with dopamine D2 receptor mRNA. Brain Res, 1991, 564, 203-219.
20. Callier S, Snapyan M, Le Crom S, Prou D, Vincent JD, Vernier P: Evolution and cell biology of dopamine receptors in vertebrates. Biol Cell, 2003, 95, 489-502.
21. Carvey PM, Pieri S, Ling ZD: Attenuation of levodopa-induced toxicity in mesencephalic cultures by pramipexole. J Neural Transm, 1997, 104, 209-228.
22. Cassarino DS, Fall CP, Smith TS, Bennett JP Jr: Pramipexole reduces reactive oxygen species production in vivo and in vitro and inhibits the mitochondrial permeability transition produced by the parkinsonian neurotoxin methylpyridinium ion. J Neurochem, 1998, 71, 295-301.
23. Chase TN, Mouradian MM, Engber TM: Motor response complications and the function of striatal efferent systems. Neurology, 1993, 43, S23-S27.
24. Chaudhuri KR, Dhawan V, Basu S, Jackson G, Odin P: Valvular heart disease and fibrotic reactions may be related to ergot dopamine agonists, but non-ergot agonists may also not be spared. Mov Disord, 2004, 19, 1522-1523.
25. Cheer SM, Bang LM, Keating GM: Ropinirole: for the treatment of restless legs syndrome. CNS Drugs, 2004, 18, 747-754.
26. Clarke CE, Deane KH: Ropinirole versus bromocriptine for levodopa-induced complications in Parkinson's disease. Cochrane Database Syst Rev, 2001, CDO01517.
27. Coppi G: Neuroprotective activity of alphadihydroergocryptine in animal models. J Neural Transm Suppl, 1995, 45, 307-318.
28. Deleu D, Hanssens Y, Northway MG: Subcutaneous apomorphine: an evidence-based review of its use in Parkinson's disease. Drugs Aging, 2004, 21, 687-709.
29. Diaz J, Levesque D, Griffon N, Lammers CH, Martres MP, Sokoloff P, Schwartz JC: Opposing roles for dopamine D2 and D3 receptors on neurotensin mRNA expression in nucleus accumbens. Eur J Neurosci, 1994, 6, 1384-1387.
30. Diaz J, Levesque D, Lammers CH, Griffon N, Martres MP, Schwartz JC, Sokoloff P: Phenotypical characterization of neurons expressing the dopamine D3 receptor in the rat brain. Neuroscience, 1995, 65, 731-745.
31. Diaz J, Ridray S, Mignon V, Griffon N, Schwartz JC, Sokoloff P: Selective expression of dopamine D3 receptor mRNA in proliferative zones during embryonic development of the rat brain. J Neurosci, 1997, 17, 4282-4292.
32. Dziewczapolski G, Murer G, Agid Y, Gershanik O, Raisman-Vozari R: Absence of neurotoxicity of chronic L-DOPA in 6-hydroxydopamine-lesioned rats. Neuroreport, 1997, 8, 975-979.
33. Eden RJ, Costall B, Domeney AM, Gerrard PA, Harvey CA, Kelly ME, Naylor RJ, Owen DA, Wright A: Preclinical pharmacology of ropinirole (SK&F 101468-A) a novel dopamine D2 agonist. Pharmacol Biochem Behav, 1991, 38, 147-154.
34. Fahn S: Controversies in the therapy of Parkinson's disease. Adv Neurol, 1996, 69, 477-486.
35. Fahn S, Cohen G: The oxidant stress hypothesis in Parkinson's disease: evidence supporting it. Ann Neurol, 1992, 32, 804-812.
36. Favit A, Sortino MA, Aleppo G, Scapagnini U, Canonico PL: Protection by dihydroergocryptine of glutamate-induced neurotoxicity. Pharmacol Toxicol, 1993, 73, 224-228.
37. Favit A, Sortino MA, Aleppo G, Scapagnini U, Canonico PL: The inhibition of peroxide formation as a possible substrate for the neuroprotective action of dihydroergocryptine. J Neural Transm Suppl, 1995, 45, 297-305.
38. Felten DL, Felten SY, Fuller RW, Romano TD, Smalstig EB, Wong DT, Clemens JA: Chronic dietary pergolide preserves nigrostriatal neuronal integrity in aged-Fischer-344 rats. Neurobiol Aging, 1992, 13, 339-351.
39. Ferger B, Teismann P, Mierau J: The dopamine agonist pramipexole scavenges hydroxyl free radicals induced by striatal application of 6-hydroxydopamine in rats: an in vivo microdialysis study. Brain Res, 2000, 883, 216-223.
40. Ferrario JE, Delfino MA, Stefano AV, Zbarsky V, Douhou A, Murer MG, Raisman-Vozari R, Gershanik OS: Effects of orally administered levodopa on mesencephalic dopaminergic neurons undergoing a degenerative process. Neurosci Res, 2003, 47, 431-436.
41. Foley P, Gerlach M, Double KL, Riederer P: Dopamine receptor agonists in the therapy of Parkinson's disease. J Neural Transm, 2004, 111, 1375-1446.
42. Gassen M, Glinka Y, Pinchasi B, Youdim MB: Apomorphine is a highly potent free radical scavenger in rat brain mitochondrial fraction. Eur J Pharmacol, 1996, 308, 219-225.
43. Gerfen CR, Engber TM, Mahan LC, Susel Z, Chase TN, Monsma FJ Jr, Sibley DR: D1 and D2 dopamine receptor-regulated gene expression of striatonigral and striatopallidal neurons. Science, 1990, 250, 1429-1432.
44. Gerlach M, Double K, Arzberger T, Leblhuber F, Tatschner T, Riederer P: Dopamine receptor agonists in current clinical use: comparative dopamine receptor binding profiles defined in the human striatum. J Neural Transm, 2003, 110, 1119-1127.
45. Gille G, Radad K, Reichmann H, Rausch WD: a-Dihydroergocryptine combined with L-DOPA or dopamine promotes the survival of dopaminergic neurons in culture. J Neural Transm, 2005, (in press).
46. Gille G, Rausch WD, Hung ST, Moldzio R, Janetzky B, Hundemer HP, Kolter T, Reichmann H: Pergolide protects dopaminergic neurons in primary culture under stress conditions. J Neural Transm, 2002, 109, 633-643.
47. Goetz CG, Diederich NJ: Dopaminergic agonists in the treatment of Parkinson's disease. Neurol Clin, 1992, 10, 527-540.
48. Gomez-Vargas M, Nishibayashi-Asanuma S, Asanuma M, Kondo Y, Iwata E, Ogawa N: Pergolide scavenges both hydroxyl and nitric oxide free radicals in vitro and inhibits lipid peroxidation in different regions of the rat brain. Brain Res, 1998, 790, 202-208.
49. Grandy DK, Zhang YA, Bouvier C, Zhou QY, Johnson RA, Allen L, Buck K et al.: Multiple human D5 dopamine receptor genes: a functional receptor and two pseudogenes. Proc Natl Acad Sci USA, 1991, 88, 9175-9179.
50. Grunblatt E, Mandel S, Berkuzki T, Youdim MB: Apomorphine protects against MPTP-induced neurotoxicity in mice. Mov Disord, 1999, 14, 612-618.
51. Gu M, Irvani M, Cooper JM, King D, Jenner P, Schapira AH: Pramipexole protects against apoptotic cell death by non-dopaminergic mechanisms. J Neurochem, 2004, 91, 1075-1081.
52. Guo H, Tang Z, Yu Y, Xu L, Jin G, Zhou J: Apomorphine induces trophic factors that support fetal rat mesencephalic dopaminergic neurons in cultures. Eur J Neurosci, 2002, 16, 1861-1870.
53. Harrison MB, Wiley RG, Wooten GF: Selective localization of striatal D1 receptors to striatonigral neurons. Brain Res, 1990, 528, 317-322.
54. Hoglinger GU, Rizk P, Muriel MP, Duyckaerts C, Oertel WH, Caille I, Hirsch EC: Dopamine depletion impairs precursor cell proliferation in Parkinson disease. Nat Neurosci, 2004, 7, 726-735.
55. Horvath J, Fross RD, Kleiner-Fisman G, Lerch R, Stalder H, Liaudat S, Raskoff WJ et al.: Severe multivalvular heart disease: a new complication of the ergot derivative dopamine agonists. Mov Disord, 2004, 19, 656-662.
56. Iida M, Miyazaki I, Tanaka K, Kabuto H, Iwata-Ichikawa E, Ogawa N: Dopamine D2 receptor-mediated antioxidant and neuroprotective effects of ropinirole, a dopamine agonist. Brain Res, 1999, 838, 51-59.
57. Jaber M, Robinson SW, Missale C, Caron MG: Dopamine receptors and brain function. Neuropharmacology, 1996, 35, 1503-1519.
58. Jackson DM, Westlind-Danielsson A: Dopamine receptors: molecular biology, biochemistry and behavioral aspects. Pharmacol Ther, 1994, 64, 291-370.
59. Jankovic J, Orman J: Parallel double-blind study of pergolide in Parkinson's disease. Adv Neurol, 1987, 45, 551-554.
60. Jenner P: Dopamine agonists, receptor selectivity and dyskinesia induction in Parkinson's disease. Curr Opin Neurol, 2003, 16, S3-S7.
61. Jenner P, Olanow CW: Oxidative stress and the pathogenesis of Parkinson's disease. Neurology, 1996, 47, S161-S170.
62. Kapsimali M, Vidal B, Gonzalez A, Dufour S, Vernier P: Distribution of the mRNA encoding the four dopamine D(1) receptor subtypes in the brain of the European eel (Anguilla anguilla): comparative approach to the function of D(1) receptors in vertebrates. J Comp Neurol, 2000, 419, 320-343.
63. Kebabian JW, Calne DB: Multiple receptors for dopamine. Nature, 1979, 277, 93-96.
64. Khan ZU, Gutierrez A, Martin R, Penafiel A, Rivera A, de la CA: Dopamine D5 receptors of rat and human brain. Neuroscience, 2000, 100, 689-699.
65. Kitamura Y, Kosaka T, Kakimura JI, Matsuoka Y, Kohno Y, Nomura Y, Taniguchi T: Protective effects of the antiparkinsonian drugs talipexole and pramipexole against 1-methyl-4-phenylpyridinium-induced apoptotic death in human neuroblastoma SH-SY5Y cells. Mol Pharmacol, 1998, 54, 1046-1054.
66. Kitamura Y, Taniguchi T, Shimohama S, Akaike A, Nomura Y: Neuroprotective mechanisms of antiparkinsonian dopamine D2-receptor subfamily agonists. Neurochem Res, 2003, 28, 1035-1040.
67. Kohno Y, Takeuchi S: Pharmacological profiles and clinical effects of antiparkinsonian agent, pramipexole (Japanese). Nippon Yakurigaku Zasshi, 2004, 123, 429-440.
68. Kondo T, Ito T, Sugita Y: Bromocriptine scavenges methamphetamine-induced hydroxyl radicals and attenuates dopamine depletion in mouse striatum. Ann NY Acad Sci, 1994, 738, 222-229.
69. Kuzel MD: Ropinirole: a dopamine agonist for the treatment of Parkinson's disease. Am J Health Syst Pharm, 1999, 56, 217-224.
70. Lai CT, Yu PH: Dopamine- and L-beta-3,4-dihydroxyphenylalanine hydrochloride (L-Dopa)-induced cytotoxicity towards catecholaminergic neuroblastoma SH-SY5Y cells. Effects of oxidative stress and antioxidative factors. Biochem Pharmacol, 1997, 53, 363-372.
71. Le Moine C, Bloch B: Expression of the D3 dopamine receptor in peptidergic neurons of the nucleus accumbens: comparison with the D1 and D2 dopamine receptors. Neuroscience, 1996, 73, 131-143.
72. Le WD, Jankovic J: Are dopamine receptor agonists neuroprotective in Parkinson's disease? Drugs Aging, 2001, 18, 389-396.
73. Le WD, Jankovic J, Xie W, Appel SH: Antioxidant property of pramipexole independent of dopamine receptor activation in neuroprotection. J Neural Transm, 2000, 107, 1165-1173.
74. Ling ZD, Pieri SC, Carvey PM: Comparison of the neurotoxicity of dihydroxyphenylalanine stereoisomers in cultured dopamine neurons. Clin Neuropharmacol, 1996, 19, 360-365.
75. Luedtke RR, Mach RH: Progress in developing D3 dopamine receptor ligands as potential therapeutic agents for neurologcal and neuropsychiatrc disorders. Curr Pharm Des, 2003, 9, 643-671.
76. Marek K, Jennings D, Seibyl J: Single-photon emission tomography and dopamine transporter imaging in Parkinson's disease. Adv Neurol, 2003, 91, 183-191.
77. Martignoni E, Pacchetti C, Sibilla L, Bruggi P, Pedevilla M, Nappi G: Dihydroergocryptine in the treatment of Parkinson's disease: a six months' double-blind clinical trial. Clin Neuropharmacol, 1991, 14, 78-83.
78. Medico M, De Vivo S, Tomasello C, Grech M, Nicosia A, Castorina M, D'Agata MA et al.: Behavioral and neurochemical effects of dopaminergic drugs in models of brain injury Eur Neuropsychopharmacol, 2002, 12, 187-194.
79. Mengod G, Martinez-Mir MI, Vilaro MT, Palacios JM: Localization of the mRNA for the dopamine D2 receptor in the rat brain by in situ hybridization histochemistry. Proc Natl Acad Sci USA, 1989, 86, 8560-8564.
80. Metman LV, Konitsiotis S, Chase TN: Pathophysiology of motor response complications in Parkinson's disease: hypotheses on the why, where, and what. Mov Disord, 2000, 15, 3-8.
81. Mierau J, Schingnitz G: Biochemical and pharmacological studies on pramipexole, a potent and selective dopamine D2 receptor agonist. Eur J Pharmacol, 1992, 215, 161-170.
82. Mierau J, Schneider FJ, Ensinger HA, Chio CL, Lajiness ME, Huff RM: Pramipexole binding and activation of cloned and expressed dopamine D2, D3 and D4 receptors. Eur J Pharmacol, 1995, 290, 29-36.
83. Minea D, Varga I, Falup-Pecurariu C, de Mey C, Retzow A, Althaus M: Influence of the dopamine agonist alphadihydroergocryptine on the pharmacokinetics of levodopa in patients with Parkinson's disease. Clin Neuropharmacol, 2001, 24, 235-238.
84. Missale C, Nash SR, Robinson SW, Jaber M, Caron MG: Dopamine receptors: from structure to function. Physiol Rev, 1998, 78, 189-225.
85. Morelli M, Mennini T, Di Chiara G: Nigral dopamine autoreceptors are exclusively of the D2 type: quantitative autoradiography of [125I]iodosulpride and [125I]SCH 23982 in adjacent brain sections. Neuroscience, 1988, 27, 865-870.
86. Muler HV, Matthiessen HP, Schmalenbach C, Schroeder WO: Glial support of CNS neuronal survival, neurite outgrowth and regeneration. Restor Neurol Neurosci, 1991, 2, 229-232.
87. Murer MG, Dziewczapolski G, Menalled LB, Garcia MC, Agid Y, Gershanik O, Raisman-Vozari R: Chronic levodopa is not toxic for remaining dopamine neurons, but instead promotes their recovery, in rats with moderate nigrostriatal lesions. Ann Neurol, 1998, 43, 561-575.
88. Muriel MP, Bernard V, Levey AI, Laribi O, Abrous DN, Agid Y, Bloch B, Hirsch EC: Levodopa induces a cytoplasmic localization of D1 dopamine receptors in striatal neurons in Parkinson's disease. Ann Neurol, 1999, 46, 103-111.
89. Muriel MP, Orieux G, Hirsch EC: Levodopa but not ropinirole induces an internalization of D1 dopamine receptors in parkinsonian rats. Mov Disord, 2002, 17, 1174-1179.
90. Mytilineou C, Han SK, Cohen G: Toxic and protective effects of L-dopa on mesencephalic cell cultures. J Neurochem, 1993, 61, 1470-1478.
91. Nutt JG: Clinical pharmacology of levodopa-induced dyskinesia. Ann Neurol, 2000, 47, S160-S164.
92. Ogawa N, Tanaka K, Asanuma M, Kawai M, Masumizu T, Kohno M, Mori A: Bromocriptine protects mice against 6-hydroxydopamine and scavenges hydroxyl free radicals in vitro. Brain Res, 1994, 657, 207-213.
93. Ohta K, Fujinami A, Kuno S, Sakakimoto A, Matsui H, Kawahara Y, Ohta M: Cabergoline stimulates synthesis and secretion of nerve growth factor, brain-derived neurotrophic factor and glial cell line-derived neurotrophic factor by mouse astrocytes in primary culture. Pharmacology, 2004, 71, 162-168.
94. Olanow CW: A radical hypothesis for neurodegeneration. Trends Neurosci, 1993, 16, 439-444.
95. Opacka-Juffry J, Wilson AW, Blunt SB: Effects of pergolide treatment on in vivo hydroxyl ftee radical formation during infusion of 6-hydroxydopamine in rat striatum. Brain Res, 1998, 810, 27-33.
96. Ossowska K, Wardas J, Kuter K, Nowak P, Dabrowska J, Bortel A, Labus L et al.: Influence of paraquat on dopaminergic transporter in the rat brain. Pharmacol Rep, 2005, 57, 330-335.
97. Pardo B, Mena MA, De Yebenes JG: L-dopa inhibits complex IV of the electron transport chain in catecholamine-rich human neuroblastoma NB69 cells. J Neurochem, 1995, 64, 576-582.
98. Parkinson Study Group: Dopamine transporter brain imaging to assess the effects of pramipexole vs. levodopa on Parkinson's disease progression. JAMA, 2002, 287, 1653-1661.
99. Paulus W, Jellinger K: The neuropathologic basis of different clinical subgroups of Parkinson's disease. J Neuropathol Exp Neurol, 1991, 50, 743-755.
100. Pedrosa R, Soares-da-Silva P: Oxidative and non-oxidative mechanisms of neuronal cell death and apoptosis by L-3,4-dihydroxyphenylalanine (L-DOPA) and dopamine. Br J Pharmacol, 2002, 137, 1305-1313.
101. Perry TL, Yong VW, Ito M, Foulks JG, Wall RA, Godin DV, Clavier RM: Nigrostriatal dopaminergic neurons remain undamaged in rats given high doses of L-DOPA and carbidopa chronically. J Neurochem, 1984, 43, 990-993.
102. Pilon C, Levesque D, Dimitriadou V, Griffon N, Martres MP, Schwartz JC, Sokoloff P: Functional coupling of the human dopamine D3 receptor in a transfected NG 108-15 neuroblastoma-glioma hybrid cell line. Eur J Pharmacol, 1994, 268, 129-139.
103. Pirtosek Z, Flisar D: Neuroprotection and dopamine agonists. Adv Exp Med Biol, 2004, 541, 55-74.
104. Popperl G, Tatsch K, Ruzicka E, Storch A, Gasser T, Schwarz J: Comparison of alpha-dihydroergocryptine and levodopa monotherapy in Parkinson's disease: assessment of changes in DAT binding with [(123)I]IPT SPECT. J Neural Transm, 2004, 111, 1041-1052.
105. Quinn N, Parkes D, Janota I, Marsden CD: Preservation of the substantia nigra and locus coeruleus in a patient receiving levodopa (2 kg) plus decarboxylase inhibitor over a four-year period. Mov Disord, 1986, 1, 65-68.
106. Ramirez AD, Wong SK, Menniti FS: Pramipexole inhibits MPTP toxicity in mice by dopamine D3 receptor dependent and independent mechanisms. Eur J Pharmacol, 2003, 475, 29-35.
107. Rascol O, Pathak A, Bagheri H, Montastruc JL: New concerns about old drugs: Valvular heart disease on ergot derivative dopamine agonists as an exemplary situation of pharmacovigilance. Mov Disord, 2004, 19, 611-613.
108. Reichmann H: Long-term treatment with dopamine agonists in idiopathic Parkinson's disease. J Neurol, 2000, 247, Suppl 4, IV 17-IV 19.
109. Reichmann H, Brecht MH, Koster J, Kraus PH, Lemke MR: Pramipexole in routine clinical practice: a prospective observational trial in Parkinson's disease. CNS Drugs, 2003, 17, 965-973.
110. Rinne UK, Bracco F, Chouza C, Dupont E, Gershanik O, Marti Masso JF, Montastruc JL, Marsden CD: Early treatment of Parkinson's disease with cabergoline delays the onset of motor complications. Results of a doubleblind levodopa controlled trial. The PKDS009 Study Group. Drugs, 1998, 55, Suppl 1, 23-30.
111. Roceri M, Molteni R, Fumagalli F, Racagni G, Gennarelli M, Corsini G, Maggio R, Riva M: Stimulatory role of dopamine on fibroblast growth factor-2 expression in rat striatum. J Neurochem, 2001, 76, 990-997.
112. Sam EE, Verbeke N: Free radical scavenging properties of apomorphine enantiomers and dopamine: possible implication in their mechanism of action in parkinsonism. J Neural Transm Park Dis Dement Sect, 1995, 10, 115-127.
113. Schapira AH: Neuroprotection in PD - A role for dopamine agonists? Neurology, 2003, 61, S34-S42.
114. Schrag A, Keens J, Warner J: Ropinirole for the treatment of tremor in early Parkinson's disease. Eur J Neurol, 2002, 9, 253-257.
115. Schwartz JC, Giros B, Martres MP, Sokoloff P: The dopamine receptor family: molecular biology and pharmacology. The Neurosciences, 1992, 4, 99-108.
116. Schwarz J: Rationale for dopamine agonist use as monotherapy in Parkinson's disease. Curr Opin Neurol, 2003, 16, Suppl 1, S27-S33.
117. Sealfon SC, Olanow CW: Dopamine receptors: from structure to behavior. Trends Neurosci, 2000, 23, S34-S40.
118. Serratrice J, Disdier P, Habib G, Viallet F, Weiller PJ: Fibrotic valvular heart disease subsequent to bromocriptine treatment. Cardiol Rev, 2002, 10, 334-336.
119. Sokoloff P, Giros B, Martres MP, Bouthenet ML, Schwartz. JC: Molecular cloning and characterization of a novel dopamine receptor (D3) as a target for neuroleptics. Nature, 1990, 347, 146-151.
120. Spina MB, Cohen G: Exposure of striatal [corrected] synaptosomes to L-dopa increases levels of oxidized glutathione. J Pharmacol Exp Ther, 1988, 247, 502-507.
121. Sunahara RK, Guan HC, O'Dowd BF, Seeman P, Laurier LG, Ng G, George SR et al.: Cloning of the gene for a human dopamine D5 receptor with higher affinity for dopamine than D1. Nature, 1991, 350, 614-619.
122. Takashima H, Tsujihata M, Kishikawa M, Freed WJ: Bromocriptine protects dopaminergic neurons from levodopa-induced toxicity by stimulating D(2)receptors. Exp Neurol, 1999, 159, 98-104.
123. Tanaka K, Miyazaki I, Fujita N, Haque ME, Asanuma M, Ogawa N: Molecular mechanism in activation of glutathione system by ropinirole, a selective dopamine D2 agonist. Neurochem Res, 2001, 26, 31-36.
124. Ubeda A, Montesinos C, Paya M, Alearaz MJ: Iron-reducing and free-radical-scavenging properties of apomorphine and some related benzylisoquinolines. Free Radic Biol Med, 1993, 15, 159-167.
125. Uberti D, Carsana T, Francisconi S, Toninelli GF, Canonico PL, Memo M: A novel mechanism for pergolide-induced neuroprotection: inhibition of NF-kappaB nuclear translocation. Biochem Pharmacol, 2004, 67, 1743-1750.
126. Uberti D, Piccioni L, Colzi A, Bravi D, Canonico PL, Memo M: Pergolide protects SH-SY5Y cells against neurodegeneration induced by H(2)O(2). Eur J Pharmacol, 2002, 434, 17-20.
127. Vallone D, Picetti R, Borrelli E: Structure and function of dopamine receptors. Neurosci Biobehav Rev, 2000, 24, 125-132.
128. Van Camp G, Flamez A, Cosyns B, Weytjens C, Muyldermans L, Van Zandijcke M, De Sutter J et al.: Treatment of Parkinson's disease with pergolide and relation to restrictive valvular heart disease. Lancet, 2004, 363, 1179-1183.
129. Van Kampen JM, Hagg T, Robertson HA: Induction of neurogenesis in the adult rat subventricular zone and neostriatum following dopamine D receptor stimulation. Eur J Neurosci, 2004, 19, 2377-2387.
130. Vincenzi FF, Hinds TR: Pramipexole has antioxidant properties and inhibits lipid peroxidation. Proc West Pharmacol Soc, 1998, 41, 43-46.
131. Von Voigtlander PF, Fici GJ, Althaus JS: Pharmacological approaches to counter the toxicity of Dopa. Amino Acids, 1998, 14, 189-196.
132. Vu TQ, Ling ZD, Ma SY, Robie HC, Tong CW, Chen EY, Lipton JW, Carvey PM: Pramipexole attenuates the dopaminergic cell loss induced by intraventricular 6-hydroxydopamine. J Neural Transm, 2000, 107, 159-176.
133. Waller EA, Kaplan J, Heckman MG: Valvular heart disease in patients taking pergolide. Mayo Clin Proc, 2005, 80, 1016-1020.
134. Watts RL: The role of dopamine agonists in early Parkinson's disease. Neurology, 1997, 49, S34-S48.
135. Whone AL, Watts RL, Stoessl AJ, Davis M, Reske S, Nahmias C, Lang AE et al.: Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL-PET study. Ann Neurol, 2003, 54, 93-101.
136. Widnell K: Pathophysiology of motor fluctuations in Parkinson's disease. Mov Disord, 2005, 20, Suppl 11, S17-S22.
137. Wiseman LR, Fitton A: Cabergoline. A review of its efficacy in the treatment of Parkinson's disease. CNS Drugs, 1999, 12, 485-497.
138. Yoshikawa T, Minamiyama Y, Naito Y, Kondo M: Antioxidant properties of bromocriptine, a dopamine agonist. J Neurochem, 1994, 62, 1034-1038.
139. Yoshioka M, Tanaka K, Miyazaki I, Fujita N, Higashi Y, Asanuma M, Ogawa N: The dopamine agonist cabergoline provides neuroprotection by activation of the glutathione system and scavenging free radicals. Neurosci Res, 2002, 43, 259-267.
140. Youdim MB, Grunblatt E, Mandel S: The pivotal role of iron in NF-kappa B activation and nigrostriatal dopaminergic neurodegeneration. Prospects for neuroprotection in Parkinson's disease with iron chelators. Ann NY Acad Sci, 1999, 890, 7-25.
141. Young BK, Camicioli R, Ganzini L: Neuropsychiatric adverse effects of antiparkinsonian drugs. Characteristics, evaluation and treatment. Drugs Aging, 1997, 10, 367-383.
142. Yuan H, Sarre S, Ebinger G, Michotte Y. Neuroprotective and neurotrophic effect of apomorphine in the striatal 6-OHDA-lesion rat model of Parkinson's disease. Brain Res, 2004, 1026, 95-107.
143. Zigmond MJ, Hastings TG, Perez RG: Increased dopamine turnover after partial loss of dopaminergic neurons: compensation or toxicity? Parkinsonism Relat Disord, 2002, 8, 389-393.
144. Zou L, Jankovic J, Rowe DB, Xie W, Appel SH, Le W: Neuroprotection by pramipexole against dopamine- and levodopa-induced cytotoxicity. Life Sci, 1999, 64, 1275-1285.